RESEARCH PEPTIDE FUNDAMENTALS / FAQ
Questions From the Trial Record
Short, citation-anchored answers to the questions readers most often bring to these four research peptides.
What is ipamorelin?
Ipamorelin is a synthetic five-amino-acid peptide that selectively activates the ghrelin receptor (GHS-R1a) on pituitary cells, triggering a short pulse of growth hormone release. It's not approved as a drug anywhere; it's sold as a research chemical. Its only human trial — a 2014 study in patients recovering from bowel surgery — did not show a statistically significant benefit [3].
What does ipamorelin do for you?
In animals, ipamorelin reliably triggers a single growth-hormone pulse from the pituitary and increases bone growth rate at higher doses [5]. In humans, the evidence is much thinner: the one controlled trial that exists tested recovery after bowel surgery and found no significant benefit over placebo [3]. Community reports describe sleep and recovery effects, but those are self-reported and unverified, not measured in any trial.
What is ipamorelin peptide?
Ipamorelin is a pentapeptide — a chain of five amino acids — engineered from an older growth-hormone-releasing peptide to be more selective. It activates the ghrelin receptor without meaningfully raising cortisol or prolactin, its defining pharmacological trait. Human pharmacokinetic data show a terminal half-life of about two hours [4].
What are the risks of ipamorelin?
The honest answer is that long-term human risk data doesn't exist — the entire controlled human record is one short perioperative trial [3] and one single-dose pharmacokinetic study [4]. A 28-day rat study of a related ghrelin-receptor agonist, not ipamorelin itself, found dose-dependent heart-muscle damage, the closest thing this receptor class has to a chronic cardiovascular safety signal [2]. Research-grade material also carries no pharmaceutical quality assurance.
What is NAD supplement used for?
NAD+ supplements — usually NMN or NR, since NAD+ itself is poorly absorbed intact — are marketed for energy metabolism and age-related decline. Controlled trials confirm they reliably raise blood NAD+ in a dose-dependent way [7][10]. Some trials show narrower clinical effects too: ten weeks of NMN improved muscle insulin sensitivity in prediabetic women on formal clamp testing [8]. A hard clinical-outcome trial for aging itself doesn't exist yet [6].
What is the downside of taking NAD+?
The clearest documented downside involves delivery, not the molecule: compounded, injectable NAD+ has been the subject of an FDA Class I recall over bacterial contamination. Infused NAD+ also clears the bloodstream fast, and running an infusion too quickly is linked to nausea, flushing, and chest or abdominal discomfort. On the supplement side, oral NAD+ itself is poorly absorbed, and NMN's regulatory status as a supplement is contested.
Is it safe to take NAD daily?
The precursor trials that exist — testing NMN and NR daily for 8 to 60 days — reported no significant safety issues across a wide dose range, including at the highest doses tested [7][10]. That's a reasonable tolerability signal for the trial durations studied. What's not established is long-term safety beyond those windows, or safety in people with active cancer, given a theoretical concern that NAD+ supports the metabolism of proliferating cells generally.
Does NAD cause weight gain?
No trial on this desk reports NAD+ or its precursors causing weight gain. The clamp study in prediabetic women found no change in body composition after ten weeks of NMN, alongside an improvement in muscle insulin sensitivity [8]. Weight change isn't the endpoint these trials were built to test, so the honest answer is that it hasn't been studied directly, not that it's been ruled out.
What is thymosin alpha 1?
Thymosin alpha-1 is a 28-amino-acid immune-modulating peptide, naturally made by the thymus gland in small amounts. The synthetic drug version, thymalfasin, is approved in more than 35 countries — not including the United States [12]. It acts on dendritic cells and T-cells to help the immune system mature and respond more effectively.
What does thymosin alpha 1 do?
Mechanistically, it activates Toll-like receptors on dendritic cells, driving those cells to mature and present antigens more effectively, which in turn matures T-cells and pushes the immune response toward an infection-fighting profile. In severe COVID-19, it was associated with lower mortality and reversal of T-cell exhaustion markers in a retrospective study [13]. In sepsis, its largest and most rigorous trial — 1,106 patients — found no mortality benefit [11].
What is thymosin alpha 1 used for?
Internationally, thymalfasin is used for chronic viral infections and as an immune-supportive adjunct in specific clinical settings. It's also studied experimentally — for sepsis, where its largest trial was null [11], and in oncology, as a combination-therapy adjuvant alongside chemotherapy and checkpoint inhibitors in melanoma, liver, and lung cancer [14].
Is thymosin alpha 1 FDA-approved?
No. Thymosin alpha-1 (thymalfasin) has no FDA marketing approval in the United States, though it is approved as a drug in more than 35 other countries [12]. US use is limited to investigational or compounded contexts.
What is tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide that activates two gut-hormone receptors at once — GIP and GLP-1. It's FDA-approved for type 2 diabetes, chronic weight management, and moderate-to-severe sleep apnea in adults with obesity [17]. Of the four compounds on this desk, it carries by far the deepest clinical-trial record.
How does tirzepatide work?
It binds both the GIP and GLP-1 receptors, increasing glucose-triggered insulin release, suppressing glucagon, and slowing stomach emptying — the combination responsible for its blood-sugar and appetite effects. Lab assays show it engages the GIP receptor more strongly than the GLP-1 receptor, with biased signaling at the GLP-1 receptor that favors one internal pathway over another [21].
What does tirzepatide do in the body?
In the pancreas, it boosts glucose-dependent insulin release and suppresses glucagon. In the gut, it slows stomach emptying, which extends fullness and contributes to nausea as a side effect. In appetite-regulating brain circuits, it reduces food-seeking behavior. In trials, this combination produced weight loss of up to -20.9% at the highest dose over 72 weeks, against -3.1% for placebo [19].
What is tirzepatide used for?
FDA-approved uses: type 2 diabetes mellitus, chronic weight management in adults with obesity or overweight plus a weight-related condition, and moderate-to-severe obstructive sleep apnea in adults with obesity. In a head-to-head Phase 3 trial, it also outperformed semaglutide directly, producing -20.2% weight loss versus -13.7% over 72 weeks [16].